Author: Jillian Dabney

Disclosure: I am in full compliance with all ethics and other policies for Market Realist research analysts. I am not invested in securities that I cover on Market Realist.

According to top-line results of Novo Nordisk's Leader trial, Victoza proved to be superior to existing treatments in reducing cardiovascular risks in patients with type two diabetes.

Global big pharmaceutical companies that have major exposure to Europe will be impacted significantly by Brexit. The depreciating euro will impact sales.

Analysts expected Valeant to record $2.5 billion and $2.6 billion in total revenue during 3Q16 and 4Q16. The yearly revenue will fall 9.6% during 3Q16.

Amgen’s top-line growth is under pressure following the rising competition for key drug Enbrel, which had a 26% share in Amgen’s total product sales in 3Q16.

On December 8, 2016, Horizon Pharma (HZNP) announced that its Phase 3 STEADFAST trial for Actimmune didn't meet its primary endpoint. Horizon stock fell 22.5% that day.

As of November 1, Pfizer had ~94 projects in various development stages. More than 40% of these projects are in phase three or the registration phase.

Considering the robust growth prospects for many of its products going forward, Pfizer should return to robust top line growth.

On an annual basis, MNK’s net sales soared by 16% to $3.4 billion in 2016. Despite its better-than-estimated performance, shares fell by 9% on November 29.

In this series, we’ll discuss Valeant Pharmaceuticals’ growth prospects, challenges, and whether it could be a good bet for investment.

Mallinckrodt (MNK) has recently been making news due to its business model being questioned. A Citron Research report focused on the sustainability of Acthar’s higher level of exposure to government-oriented franchise.